Callréus, Torbjörn http://orcid.org/0000-0001-9903-5817
El-Galaly, Tarec Christoffer http://orcid.org/0000-0002-4406-380X
Jerkeman, Mats http://orcid.org/0000-0003-4509-6707
de Nully Brown, Peter http://orcid.org/0000-0002-6522-4086
Andersen, Morten http://orcid.org/0000-0001-7029-2860
Funding for this research was provided by:
Novo Nordisk Fonden (NNF15SA0018404)
Article History
First Online: 13 March 2019
Compliance with Ethical Standards
:
: Morten Andersen and Torbjörn Callréus belong to the Pharmacovigilance Research Group at the Department of Drug Design and Pharmacology, University of Copenhagen, receiving funding by the Novo Nordisk Foundation (NNF15SA0018404). No funding was specifically received for the preparation of this article.
: Mats Jerkeman has received research grants from Gilead, Abbvie, Janssen and Celgene, and personal fees from Gilead, Janssen, Acerta, Roche and Celgene. Tarec Christoffer El-Galaly has received travel grants from Takeda (ICML 2017) and Roche (ASH 2016) and has been employed by F. Hoffmann-La Roche, Ltd. since January 2019. Morten Andersen has participated in research projects funded by AstraZeneca, H. Lundbeck & Mertz, Novartis, Pfizer and Janssen, with grants paid to the institutions where he has been employed, and has personally received fees from Medicademy, the Danish Pharmaceutical Industry Association, for leading and teaching pharmacoepidemiology courses. Torbjörn Callréus and Peter de Nully Brown have no conflicts of interest that are directly relevant to the content of this article.